Journals / The Anatolian Journal of Cardiology / 2019 / Cilt: 21 - Sayı: 5

Treatment with metformin prevents myocardial ischemia–reperfusion injury via STEAP4 signaling pathway

Pages
261–271
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, STEAP4 might be a new target to decrease apoptosis and rescue mitochondrial function in myocardial I/Rinjury. (Anatol J Cardiol 2019; 21: 261-71)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of the present study was to investigate the underlying mechanism of metformin in reducing myocardial apoptosis and improving mitochondrial function in rats and H9c2 cells subjected to myocardial ischemia–reperfusion (I/R) or hypoxia–reoxygenation (H/R) injuries,respectively.Methods: Following pretreatment with metformin, male Sprague–Dawley rats were used to establish an I/R model in vivo.
📊
Key Findings & Data:H9c2 cells were used to establish an H/R model in vitro.
💡
Conclusion & Impact:Therefore, STEAP4 might be a new target to decrease apoptosis and rescue mitochondrial function in myocardial I/Rinjury. (Anatol J Cardiol 2019; 21: 261-71)
🔬Design:Modeling & Simulation
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Özet

Objective: The aim of the present study was to investigate the underlying mechanism of metformin in reducing myocardial apoptosis and improving mitochondrial function in rats and H9c2 cells subjected to myocardial ischemia–reperfusion (I/R) or hypoxia–reoxygenation (H/R) injuries,respectively.Methods: Following pretreatment with metformin, male Sprague–Dawley rats were used to establish an I/R model in vivo. Serum creatininekinase-MB and cardiac troponin T levels were examined by enzyme-linked immunosorbent assay. Infarct size and apoptosis were measuredby triphenyl tetrazolium chloride staining and terminal deoxynucleotidyl transferase dUTP nick end labeling assay. Pathological changes wereevaluated by hematoxylin and eosin staining. H9c2 cells were used to establish an H/R model in vitro. Cell apoptosis and mitochondrial membrane potential (MMP) were examined by flow cytometry and Rhodamine 123. The expression levels of six-transmembrane epithelial antigen ofprostate 4 (STEAP4), B-cell lymphoma 2, Bcl-2-associated X protein, and glyceraldehyde 3-phosphate dehydrogenase in both myocardial tissuesand H9c2 cells were determined by western blotting.Results: We found that metformin decreased infarct size, increased STEAP4 expression, mitigated myocardial apoptosis, and increased MMPwhen the models were subjected to H/R or I/R injuries. However, STEAP4 knockdown significantly abrogated the beneficial effect of metformin.Conclusion: We further demonstrated the protective effect of metformin on cardiomyocytes, which might be at least partly attributable to theupregulation of STEAP4. Therefore, STEAP4 might be a new target to decrease apoptosis and rescue mitochondrial function in myocardial I/Rinjury. (Anatol J Cardiol 2019; 21: 261-71)

🔖

Cite This Article

LUO, T., ZENG, X., YANG, W., ZHANG, Y. (2019). Treatment with metformin prevents myocardial ischemia–reperfusion injury via STEAP4 signaling pathway. The Anatolian Journal of Cardiology, Cilt: 21 - Sayı: 5, 261–271. https://ajindex.com/articles/365765

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Bainey KR, Armstrong PW. Clinical perspectives on reperfusion injury in acute myocardial infarction. Am Heart J 2014; 167: 637-45
  2. Plakht Y, Gilutz H, Shiyovich A. Excess long-term mortality among hospital survivors of acute myocardial infarction. Soroka Acute Myocardial Infarction (SAMI) project. Public Health 2017; 143: 25-36
  3. Gerczuk PZ, Kloner RA. An update on cardioprotection: a review of the latest adjunctive therapies to limit myocardial infarction size in clinical trials. J Am Coll Cardiol 2012; 59: 969-78
  4. Neri M, Riezzo I, Pascale N, Pomara C, Turillazzi E. Ischemia/Reperfusion Injury following Acute Myocardial Infarction: A Critical Issue for Clinicians and Forensic Pathologists. Mediators Inflamm 2017; 2017: 7018393
  5. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003; 285: H579-88
  6. Donato M, Evelson P, Gelpi RJ. Protecting the heart from ischemia/ reperfusion injury: an update on remote ischemic preconditioning and postconditioning. Curr Opin Cardiol 2017; 32: 784-90
  7. Natali A, Ferrannini E. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia 2006; 49: 434-41
  8. Khan SZ, Rivero M, Nader ND, Cherr GS, Harris LM, Dryjski ML, et al. Metformin Is Associated with Improved Survival and Decreased Cardiac Events with No Impact on Patency and Limb Salvage after Revascularization for Peripheral Arterial Disease. Ann Vasc Surg 2019; 55: 63-77
  9. Retwiński A, Kosmalski M, Crespo-Leiro M, Maggioni A, Opolski G, Ponikowski P, et al. The influence of metformin and the presence of type 2 diabetes mellitus on mortality and hospitalisation in patients with heart failure. Kardiol Pol 2018; 76: 1336-43
  10. Kinaan M, Ding H, Triggle CR. Metformin: An Old Drug for the Treatment of Diabetes but a New Drug for the Protection of the Endothelium. Med Princ Pract 2015; 24: 401-15
  11. Pandey A, Kumar VL. Protective Effect of Metformin against Acute Inflammation and Oxidative Stress in Rat. Drug Dev Res 2016; 77: 278-84
  12. Varjabedian L, Bourji M, Pourafkari L, Nader ND. Cardioprotection by Metformin: Beneficial Effects Beyond Glucose Reduction. Am J Cardiovasc Drugs 2018; 18: 181-93
  13. Calvert JW, Gundewar S, Jha S, Greer JJ, Bestermann WH, Tian